Filing Details
- Accession Number:
- 0000950170-24-106530
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-09-13 18:39:14
- Reporting Period:
- 2024-09-12
- Accepted Time:
- 2024-09-13 18:39:14
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1572616 | Fractyl Health Inc. | GUTS | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1419217 | David Jay Caplan | 3 Van De Graaff Drive Suite 200 Burlington MA 01803 | President, Chief Product Off. | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-09-12 | 95,484 | $1.70 | 95,484 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-09-12 | 65,000 | $2.90 | 30,484 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option | Disposition | 2024-09-12 | 95,484 | $0.00 | 95,484 | $1.70 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2024-11-10 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 358,806 | Indirect | By Trust |
Common Stock | 118,810 | Indirect | By Family Trust |
Footnotes
- The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $2.85 to $3.06. The Reporting Person undertakes to provide upon request the Staff of the Securities and Exchange Commission, the Issuer, or any stockholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- The option is fully vested and exercisable.